AXA reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 25.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,500 shares of the biotechnology company’s stock after selling 17,300 shares during the quarter. AXA owned about 0.12% of United Therapeutics worth $3,942,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in UTHR. Renaissance Technologies LLC raised its stake in United Therapeutics by 35.7% during the 2nd quarter. Renaissance Technologies LLC now owns 3,040,978 shares of the biotechnology company’s stock worth $237,379,000 after acquiring an additional 799,200 shares in the last quarter. Brandes Investment Partners LP raised its stake in United Therapeutics by 381.9% during the 2nd quarter. Brandes Investment Partners LP now owns 222,150 shares of the biotechnology company’s stock worth $17,342,000 after acquiring an additional 176,048 shares in the last quarter. Pictet Asset Management Ltd. raised its stake in United Therapeutics by 47.9% during the 2nd quarter. Pictet Asset Management Ltd. now owns 393,536 shares of the biotechnology company’s stock worth $30,719,000 after acquiring an additional 127,373 shares in the last quarter. First Trust Advisors LP raised its stake in United Therapeutics by 7.8% during the 1st quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after acquiring an additional 93,786 shares in the last quarter. Finally, Andra AP fonden acquired a new stake in United Therapeutics during the 1st quarter worth $6,350,000. Hedge funds and other institutional investors own 94.11% of the company’s stock.
UTHR has been the topic of several research analyst reports. ValuEngine upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Credit Suisse Group upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $98.00 to $101.00 in a research note on Monday, July 1st. Zacks Investment Research lowered shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $86.00 price target on the stock. in a research note on Wednesday, August 14th. Wedbush reissued a “buy” rating and set a $273.00 price objective on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, Cowen set a $118.00 price objective on shares of United Therapeutics and gave the stock a “hold” rating in a research report on Friday, September 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $121.73.
United Therapeutics stock traded up $1.14 during midday trading on Friday, hitting $81.89. 230,169 shares of the company’s stock were exchanged, compared to its average volume of 523,612. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of 6.12 and a beta of 0.95. The firm’s 50 day simple moving average is $81.64 and its 200 day simple moving average is $87.74. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.41 and a current ratio of 4.62. United Therapeutics Co. has a 12-month low of $74.31 and a 12-month high of $128.94.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 31st. The biotechnology company reported $4.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.40 by $2.26. The business had revenue of $373.60 million for the quarter, compared to the consensus estimate of $331.78 million. United Therapeutics had a negative net margin of 7.69% and a negative return on equity of 4.54%. On average, equities research analysts forecast that United Therapeutics Co. will post -1.96 EPS for the current fiscal year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Featured Story: How to trade on quiet period expirations
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.